The DIGAMI study compared “conventional” anti-diabetic therapy to intensive insulin therapy consisting of acute insulin infusion during the early hours of MI and. On the basis of these findings, the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial was started. View fulltext. DIGAMI 1 was a prospective, randomised, open-label trial with blinded endpoint evaluation (PROBE) done at coronary care units in
|Published (Last):||8 August 2018|
|PDF File Size:||6.68 Mb|
|ePub File Size:||14.81 Mb|
|Price:||Free* [*Free Regsitration Required]|
Amsterdam, Elsevier,p. Though unavoidable, this bias should be taken into consideration before making insulin therapy the standard of care. These benefits of intensive treatment were greater in the primary prevention group, whose subjects had no tria, at baseline. J Am Coll Cardiol Though the infusion group had a slightly lower mortality than the control group in the hospital 9. There is also a possibility that in the course of implementing prolonged intensive insulin therapy, patients had increased follow-up appointments and continuing care visits with their outpatient physicians.
Acute myocardial infarction in the diabetic patient: Insulin therapy has been shown to decrease tPAi-1 levels and possibly normalize the fibrinolytic process. Interestingly, the patients who appeared to have the least baseline disease benefited most from aggressive therapy.
The benefits of beta-blockade, specifically in diabetic patients, are multifaceted in nature. Summary of Results Triap characteristics The control group and the infusion group had similar demographics and pre-hospitalization characteristics. Development of new Q waves in 2 of the 12 standard electrocardiogram leads. The DIGAMI study triaal “conventional” anti-diabetic therapy to intensive insulin therapy consisting of acute insulin infusion during the early hours of MI and thrice-daily subcutaneous insulin injection for the remainder of trail hospital stay and a minimum of 3 months thereafter.
Thus, some researchers believe diabetic patients may show a greater benefit when heart rate, and thus myocardial oxygen demand, is decreased. Thus, regardless of the treatment protocol received, the in-hospital courses were similar. One such dysfunction is the increased platelet aggregation, which can be reduced with insulin administration.
Plasminogen activator in plasma, risk factor for recurrent myocardial infarction. Eur Heart J The diagnosis of MI was divided into probable or possible using conventional criteria Table 1. In this group, insulin was given in both the acute setting insulin-glucose infusion as well as throughout the year following the MI subcutaneous insulin.
Thromboxane A production and platelet aggregability have been shown to be increased in diabetic patients, fostering a hypercoagulable state. Based on these multifaceted benefits of insulin, a multicenter trial was tgial performed in Sweden to triak the effects of intravenous insulin and glucose infusions in diabetic patients who were experiencing an acute MI.
This increase in mortality is shown during both initial hospitalization and long-term follow up. In Brief People with diabetes who suffer an acute myocardial infarction MI are at markedly increased risk of future cardiovascular morbidity and mortality.
DIGAMI-2 TRIAL –
All patients in the study were classified into four pre-stratified groups according to their previous anti-diabetic management and initial cardiac risk classification. Prospective randomized study of intensive insulin treatment of long-term survival after acute myocardial infarction in patients with diabetes digmi. Kevin Mineo, MD, is is an internal medicine intern. When considering treating diabetic patients in such an aggressive manner using insulin, other social needs should be considered.
Postgrad Med J 52 Suppl 4: Though insulin may help reduce mortality ttrial theory, a trjal plan that patients are willing and able to perform may achieve more long-term success. Glucose does not require oxygen when metabolized glycolysisbut this process, as described above, is impaired by the hormonal changes that take place during MI.
Relation between serum free fatty acids and arrhythmias and death after acute myocardial infarctions.
In the past, beta-blockers grial not used in diabetic patients for fear of masking and possibly prolonging of hypoglycemic episodes. High cardiac risk was determined by two or more of the following: This impairment may potentiate ischemic heart disease by facilitating coronary artery occlusion and reocclusion. Overall, concomitant therapy was similar between both groups of the difami. This supply-demand imbalance creates an energy deficit that leads to myocardial ischemia. When viewed with other browsers, some characters or attributes may not be rendered correctly.
Mortality prediction in diabetic patients with myocardial infarction: The Diabetes Control and Complications Trial Dlgami revealed that intensive insulin therapy delayed the onset and slowed the progression of microangiopathies nephropathy, neuropathy, and retinopathy.
This advantage likely cannot be accounted for by the insulin-glucose infusion protocol alone.
By preferentially using glucose, myocardial oxygen demand decreases, and the supply-demand imbalance may be reduced. To place the DIGAMI results in perspective, it is important to note the decrease in overall mortality in diabetic patients with MI in all treatment groups.
Am J Cardiol Although improvements have been made in the treatment of cardiac disease, diabetic patients with acute MI continue to have a poor prognosis. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents: Patients who were randomized to the control group were managed according to standard coronary care practice without insulin-glucose infusion.
J Biol Chem Jennifer Cummings, MD, is an internal medicine resident. These processes not only leave these diabetic patients at higher risk of death when having an acute MI, but also increase their risk of recurrent cardiac events and other long-term complications. The change in mortality during hospitalization and at 3 months post-MI was not significant.
This is consistent with other studies that found early aggressive management may protect patients from diabetic complications. Intensive insulin therapy included an insulin-glucose triall during the initial 24 hours of hospitalization, followed by subcutaneous insulin four times daily for a minimum of 3 months.
Diabetes may be associated with severe coronary artery disease, systolic left ventricular dysfunction, autonomic neuropathy, and larger infarct size. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.